Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition. (2019)
Attributed to:
Mendelian randomization to hypothesis-free causal inference
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1161/circgen.118.002335
PubMed Identifier: 30645169
Publication URI: http://europepmc.org/abstract/MED/30645169
Type: Journal Article/Review
Volume: 12
Parent Publication: Circulation. Genomic and precision medicine
Issue: 1
ISSN: 2574-8300